Floatz logo

Recombinant Human EGF-rP64K

Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

Roswell Park Cancer InstitutePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

63 Active assets in the Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Dana-Farber Cancer Institute
Phase 4BB
Rapamycin
Dana-Farber Cancer Institute
Phase 4BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 3BB
Indocyanine Green
Institut de Cancérologie de Lorraine
Phase 3BB
Everolimus
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant Human EGF-rP64K is also rated in:

lung cancerDormant
BB
Indicative ·
65 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
head and neck squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →